Similarly to other neoplastic diseases, the treatment of GC may benefit from anti-angiogenic drugs, including ramucirumab, a monoclonal antibody antagonist of VEGFR2, currently used in the second-line therapy of GC and gastro-esophageal junction carcinomas. Here, KDR is linked to gastric cancer.